Direct to Patient Message for Patient Participation

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Yale University, New Haven, CT
Patient Participation
Direct to Patient Message - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to determine the effectiveness of enhanced features in an online patient portal including banners, a chatbot, and direct to patient message and traditional mailed letters on increasing interest in research among online patient portal users.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Patient Participation

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 12 months

12 months
Number of patients who create a research profile
Number of patients who enroll in a research study

Trial Safety

Safety Progress

1 of 3

Other trials for Patient Participation

Trial Design

16 Treatment Groups

No Intervention
1 of 16
Traditional Letter + Direct to Patient Message + Chatbot
1 of 16
Traditional Letter + Chatbot + Banner
1 of 16
Direct to Patient Message + Chatbot + Banner
1 of 16
Traditional Letter + Banner
1 of 16
Traditional Letter + Direct to Patient Message
1 of 16
Traditional Letter Only
1 of 16
Chatbot Only
1 of 16
Traditional Letter + Chatbot
1 of 16
Traditional Letter + Direct to Patient Message + Chatbot + Banner
1 of 16
Direct to Patient Message Only
1 of 16
Direct to Patient Message + Banner
1 of 16
Traditional Letter + Direct to Patient Message + Banner
1 of 16
Banner Only
1 of 16
Direct to Patient Message + Chatbot
1 of 16
Chatbot + Banner
1 of 16
Active Control
Experimental Treatment

750000 Total Participants · 16 Treatment Groups

Primary Treatment: Direct to Patient Message · No Placebo Group · N/A

Traditional Letter + Direct to Patient Message + ChatbotExperimental Group · 3 Interventions: Chatbot, Traditional Letter, Direct to Patient Message · Intervention Types: Other, Other, Other
Traditional Letter + Chatbot + BannerExperimental Group · 3 Interventions: Chatbot, Traditional Letter, Banner · Intervention Types: Other, Other, Other
Direct to Patient Message + Chatbot + BannerExperimental Group · 3 Interventions: Chatbot, Direct to Patient Message, Banner · Intervention Types: Other, Other, Other
Traditional Letter + BannerExperimental Group · 2 Interventions: Traditional Letter, Banner · Intervention Types: Other, Other
Traditional Letter + Direct to Patient MessageExperimental Group · 2 Interventions: Traditional Letter, Direct to Patient Message · Intervention Types: Other, Other
Traditional Letter Only
Other
Experimental Group · 1 Intervention: Traditional Letter · Intervention Types: Other
Chatbot Only
Other
Experimental Group · 1 Intervention: Chatbot · Intervention Types: Other
Traditional Letter + ChatbotExperimental Group · 2 Interventions: Chatbot, Traditional Letter · Intervention Types: Other, Other
Traditional Letter + Direct to Patient Message + Chatbot + BannerExperimental Group · 4 Interventions: Chatbot, Traditional Letter, Direct to Patient Message, Banner · Intervention Types: Other, Other, Other, Other
Direct to Patient Message Only
Other
Experimental Group · 1 Intervention: Direct to Patient Message · Intervention Types: Other
Direct to Patient Message + BannerExperimental Group · 2 Interventions: Direct to Patient Message, Banner · Intervention Types: Other, Other
Traditional Letter + Direct to Patient Message + BannerExperimental Group · 3 Interventions: Traditional Letter, Direct to Patient Message, Banner · Intervention Types: Other, Other, Other
Banner Only
Other
Experimental Group · 1 Intervention: Banner · Intervention Types: Other
Direct to Patient Message + ChatbotExperimental Group · 2 Interventions: Chatbot, Direct to Patient Message · Intervention Types: Other, Other
Chatbot + BannerExperimental Group · 2 Interventions: Chatbot, Banner · Intervention Types: Other, Other
No InterventionNoIntervention Group · 1 Intervention: No Intervention · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
Closest Location: Yale University · New Haven, CT
Photo of Yale University New Haven 1Photo of Yale University New Haven 2Photo of Yale University New Haven 3
1992First Recorded Clinical Trial
1 TrialsResearching Patient Participation
481 CompletedClinical Trials

Who is running the clinical trial?

Food and Drug Administration (FDA)FED
148 Previous Clinical Trials
204,333 Total Patients Enrolled
Yale UniversityLead Sponsor
1,653 Previous Clinical Trials
20,079,964 Total Patients Enrolled
1 Trials studying Patient Participation
101 Patients Enrolled for Patient Participation
Brian Smith, MDPrincipal InvestigatorYale School of Medicine

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have not set up a research profile.
You have accessed the online patient portal at least once in the past year.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.